MediRemindGLP-1 · Australia

Wegovy vs Rybelsus Australia:
Weekly Injection or Daily Tablet?

The currently available Wegovy formulation is a weekly injection; an oral Wegovy tablet was TGA-registered on 3 November 2026, with pharmacy availability still unconfirmed. Rybelsus is a separate daily tablet. All contain semaglutide but have different registrations, uses and instructions.

Quick comparison: November 2026

Wegovy

Weekly injection; oral tablet registered, launch pending

Weight management

$250–$460/month for injection, private

Rybelsus

Daily tablet

Type 2 diabetes only

PBS co-payment (T2D)

Oral Wegovy was TGA-registered on 3 November 2026; pharmacy availability was not yet confirmed on 5 November. Rybelsus is a separate oral semaglutide product registered for type 2 diabetes.

Already taking one of these medicines?

Keep your prescribed dose, reminders, eScript and remaining repeats organised in one place.

Download on the App StoreGet it on Google Play
Scan with your phone

30-day trial · Then $4.99/month or $39.99/year

MediRemind app showing Wegovy weekly injection schedule with dose stage, repeats and next reminder

MediRemind tracks your injection or tablet schedule, current prescribed dose and remaining repeats.

Published October 2026 · Fact-checked against TGA, PBS.gov.au and PBAC recommendation

Searching for "Wegovy pill" or "Wegovy tablet"?

The TGA registered oral Wegovy in Australia on 3 November 2026. A confirmed pharmacy launch date had not been announced by 5 November. Rybelsus is a separate oral semaglutide product registered for type 2 diabetes.

What is semaglutide?

Semaglutide is a GLP-1 receptor agonist, a type of medication that mimics the GLP-1 hormone, which regulates blood sugar and appetite. Novo Nordisk, the Danish pharmaceutical company, manufactures both Wegovy and Rybelsus using semaglutide as the active ingredient. Despite sharing the same active ingredient, the two products are absorbed differently, use different doses and have different approved indications. Rybelsus is registered in Australia as an oral semaglutide medicine.

Wegovy, the weekly injection for weight management

Wegovy is semaglutide in a prefilled auto-injector pen for subcutaneous injection. An injection just under the skin, typically into the abdomen, thigh or upper arm.

How you take itOne injection per week, on the same day each week.
TGA-approved forChronic weight management in eligible adults. Wegovy is also approved for reducing major cardiovascular risk in adults with established cardiovascular disease and overweight or obesity. Wegovy launched commercially in Australia in August 2024; the cardiovascular indication was approved separately in December 2024.
Dose scheduleStarts at 0.25 mg weekly, escalating every four weeks through 0.5 mg, 1.0 mg and 1.7 mg to a maintenance dose of 2.4 mg per week. The full escalation takes approximately 16 weeks.
PBS statusPBS status as at October 2026: Wegovy is not listed. Novo Nordisk lodged its listing documentation on 27 February 2026; the PBS status page, current at 1 October 2026, shows the documentation as Not Accepted, and the remaining listing steps have not started. No listing date has been announced.
Cost in AustraliaApproximately $250–$460 per month on a private prescription, depending on your current dose stage and pharmacy. The 2.4 mg maintenance dose is the most expensive.
StorageRefrigerate before first use (2–8°C). After first use, pens can be kept at room temperature below 30°C for up to six weeks.

Keep every stage of your Wegovy schedule clear

Track your weekly injection day, prescribed dose stage, repeats and next prescription date.

Track My Wegovy Schedule

30-day trial · Then $4.99/month or $39.99/year

Scan with your phone

Rybelsus, the daily tablet for Type 2 diabetes

Rybelsus is an oral GLP-1 medicine registered in Australia for Type 2 diabetes, not for weight management.

How you take itOne tablet every morning, on a completely empty stomach, with no more than 120 mL of plain water. You must wait at least 30 minutes before eating, drinking anything other than plain water, or taking other medications. Oral semaglutide has low bioavailability, food and other liquids significantly reduce how much the body absorbs.
TGA approved forType 2 diabetes mellitus in adults, as an adjunct to diet and exercise. Rybelsus is not approved in Australia for weight management.
Dose scheduleStarting dose is 3 mg daily for 30 days, then increased to 7 mg daily, with an optional further increase to 14 mg if needed.
PBS statusListed on the PBS in Australia for eligible patients with Type 2 diabetes. Patients pay the standard PBS co-payment. This subsidy does not apply if Rybelsus is prescribed off-label for weight management.
CostUp to $25 per PBS dispensing for general patients, or $7.70 for concession patients. Brand premiums or other charges may apply. Considerably less than private prescription pricing. (PBS rates current October 2026.)
StorageRoom temperature, below 30°C. No refrigeration required.

Important reminders on iPhone

With permission enabled, MediRemind can use Apple Critical Alerts so selected medication reminders can come through even when the iPhone is on Silent or Focus mode. Useful for the Rybelsus 30-minute window or a Wegovy injection day.

MediRemind is a medication management tool, not a registered medical device. Reminders, including Critical Alerts on supported iPhones, depend on device settings, user permissions and connectivity. MediRemind does not replace professional medical advice or your own awareness of your medication schedule.

Make the 30-minute morning window easier to follow

Set your reminder before breakfast and keep your prescribed dose and repeats organised.

Set Up My Rybelsus Reminder

30-day trial · Then $4.99/month or $39.99/year

Scan with your phone

Head-to-head comparison

WegovyRybelsus
Active ingredientSemaglutideSemaglutide
FormWeekly injection; oral tablet registered, launch pendingDaily tablet
TGA approved useWeight management + cardiovascular risk reductionType 2 diabetes only
PBS listedNot yet; 1 October 2026 status says listing documents Not AcceptedYes, for Type 2 diabetes
Starting dose0.25 mg weekly3 mg daily
Maintenance dose2.4 mg weekly14 mg daily
Food restrictionsNoYes, empty stomach, 30 min before food
StorageRefrigerate before first useRoom temperature
Monthly cost (approx.)$250–$460 private prescriptionPBS co-payment for T2D

No-cost tool

Build My Treatment Schedule

Tell us which medicine you take. We'll show you a personalised schedule you can save directly in MediRemind.

Which medicine are you currently taking?

PBS Waitlist

When Wegovy gets PBS-listed, the price drops by up to 90%

Enter your email and we'll send you one notification the moment a PBS listing date is confirmed, nothing else.

No spam. One email when Wegovy gets PBS-listed. Unsubscribe any time.

Is there a Wegovy pill available in Australia?

Yes. The TGA registered oral Wegovy in Australia on 3 November 2026 in four strengths: 1.5 mg, 4 mg, 9 mg and 25 mg. A confirmed pharmacy launch date had not been announced as of 5 November 2026.

Registration, pharmacy availability and PBS listing are separate milestones. Availability was anticipated later in 2026, subject to outstanding requirements. For the current registration information, check the TGA record for Novo Nordisk.

Rybelsus remains a separate oral semaglutide product registered for Type 2 diabetes. It is not an interchangeable tablet version of Wegovy.

Oral Wegovy: Australian availability updates

Get an update when Australian pharmacy availability is confirmed.

The TGA registered oral Wegovy in Australia on 3 November 2026. A pharmacy launch date had not been confirmed as of 5 November 2026. We can email you once availability is confirmed.

One email when Australian pharmacy availability is confirmed. Unsubscribe any time.

Already on the Wegovy injection? Track your schedule in MediRemind

Can I use Rybelsus for weight loss?

Rybelsus does cause weight reduction, studies in people with Type 2 diabetes showed reductions in body weight as a secondary effect. However, it is not approved or PBS-listed in Australia for weight management.

Australian doctors can legally prescribe any TGA-approved medicine off-label. That is, for a purpose other than its approved indication. If a doctor prescribes Rybelsus for weight management, you would pay the full private price, not the PBS co-payment, because the subsidy applies only to the approved Type 2 diabetes indication.

Wegovy was specifically studied and approved for chronic weight management. Rybelsus is approved in Australia for Type 2 diabetes and should not be regarded as an interchangeable tablet version of injectable Wegovy.

If weight management is your goal, speak to your doctor about which treatment is appropriate for your circumstances.

PBS Waitlist

Get notified when Wegovy's PBS price is confirmed

The difference between private and PBS cost can be hundreds of dollars a month. We'll email you the moment the listing goes live, one email, no spam.

No spam. One email when Wegovy gets PBS-listed. Unsubscribe any time.

Managing your treatment: Wegovy or Rybelsus

Both Wegovy and Rybelsus are long-term treatments. Both require you to stay on top of your schedule, your current dose stage, your repeats and your next prescription, for months or years.

If you are on Wegovy, MediRemind helps you:

  • Set a weekly injection reminder on the same day each week
  • Track your current dose stage and escalation schedule
  • See how many repeats remain on your current script
  • Get a reminder when it is time to arrange your next prescription
  • Store your eScript safely, no searching through old SMS messages
  • Manage Wegovy alongside any other medications without a pharmacy login

If you are on Rybelsus, MediRemind helps you:

  • Set a daily morning reminder early enough to take the tablet before breakfast, with time to wait the full 30 minutes
  • Track your dose stage (3 mg → 7 mg → 14 mg) and when your doctor plans to review
  • Monitor repeats remaining and refill timing
  • Store your eScript in one place

MediRemind

Weekly injection or daily tablet, keep the whole schedule in one place

Organise your prescribed dose, reminders, eScript and remaining repeats without being tied to one pharmacy.

Keep My Treatment Schedule Organised

30-day trial · Then $4.99/month or $39.99/year · iPhone and Android

Download on the App StoreGet it on Google Play
Scan with your phone

This article is for general information only and does not constitute medical or pharmaceutical advice. Information about PBS listings, TGA approvals and medication pricing is accurate at the time of writing and subject to change, verify current status at PBS.gov.au or TGA.gov.au before relying on it. Speak to your doctor or pharmacist before making any decisions about your medication or treatment. MediRemind is not affiliated with Novo Nordisk or any other pharmaceutical manufacturer.

References to weight management medications on this page are for general information only. MediRemind does not prescribe, supply or endorse any specific medication. Individual circumstances vary, speak to your doctor about which treatment is appropriate for you.